← Trials/Trial dossier/NCT03671733
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
Lead sponsor
Assets
Exenatide / Liraglutide
Listed sites
1
Recruiting sites
1
Enrollment
150
estimated
Study population
Obesity / overweight
Key I/E criterion
•BMI ≥28
Primary endpoint
•Body weight, absolute change (kg)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Patients aged 18 to 65 years (to the date of screening)；
2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm).
3. Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial.
4. Weight stable for more than 3 months (weight fluctuations <5%).
Exclusion criteria
1. pregnant female.
2. Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others.
3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis.
4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes.
5. Nearly a month had surgery, trauma, infection and so on.
6. Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators.
7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).
Endpoints (15)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
2 endpointsWeight Change at 3 months
Time frame:baseline , 3 months
Body weight, absolute change (kg)
change from baseline, improvement
Change in waist circumference
Time frame:baseline and 3 months
Waist circumference, change
change from baseline, improvement
Glycemic / diabetes
3 endpointsChange in HbA1c
Time frame:baseline and 3 months
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Change in plasma glucose
Time frame:baseline and 3 months
change from baseline, improvement
Change in insulin
Time frame:baseline and 3 months
change from baseline, improvement
Cardiometabolic biomarkers
8 endpointsChange in systolic blood pressure
Time frame:baseline and 3 months
Systolic BP, change
change from baseline, improvement
LOINC 8480-6
Change in diastolic blood pressure
Time frame:baseline and 3 months
Diastolic BP, change
change from baseline, improvement
LOINC 8462-4
Change in lipids-total cholesterol
Time frame:baseline and 3 months
Total cholesterol, change
change from baseline, improvement
LOINC 2093-3
Change in lipids-low density lipoprotein cholesterol
Time frame:baseline and 3 months
LDL-C, change
change from baseline, improvement
LOINC 13457-7
Change in lipids-high density lipoprotein cholesterol
Time frame:baseline and 3 months
HDL-C, change
change from baseline, improvement
LOINC 2085-9
Change in lipids-triglycerides
Time frame:baseline and 3 months
Triglycerides, change
change from baseline, improvement
LOINC 2571-8
Change in lipids-free fatty acids
Time frame:baseline and 3 months
Free fatty acids, change
change from baseline, improvement
Change in Uric Acid
Time frame:baseline and 3 months
change from baseline, improvement
Other (unclassified)
2 endpointsChange in interleukin-6
Time frame:baseline and 3 months
change from baseline, improvement
Change in tumor necrosis factor
Time frame:baseline and 3 months
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.